

**Important Notes:** Information mentioned in this document is intended to provide you with a general summary of the ILP Sub-Fund and are subject to change. Please read the Policy (including Policy Illustration, Product Summary and Fund Summary) for the full details of the standard terms and conditions and the exclusions of the insurance product and ILP Sub-Fund.

This Product Highlights Sheet ("PHS") is an important document.

- It highlights the key terms and risks of the ILP Sub-Fund and complements the Product Summary and Fund Summary.
- It is important to read the Product Summary and the Fund Summary before deciding whether to purchase the ILP Sub-Fund. If you do not have a copy, please contact us to ask for one.
- You should not invest in the ILP Sub-Fund if you do not understand it or are not comfortable with the accompanying risks.
- Unless otherwise defined, capitalised terms in this PHS have been defined in the Fund Summary.

Investment risk rating is used as a guide to determine the ILP Sub-Fund that is suitable to the risk profile as indicated in the Bank's Risk Profile Questionnaire (RPQ). It is currently only applicable to customers of HSBC Bank (Singapore) Limited (the "Bank").

## AB International Health Care Portfolio (the "ILP Sub-Fund")

Product Type	ILP Sub-Fund <sup>1</sup>	Launch Date	The Portfolio established on 31 August 2006
Manager	AllianceBernstein (Luxembourg) S.a r.l.	Custodian	Brown Brothers Harriman (Luxembourg) S.C.A
Capital Guaranteed	No	Dealing Frequency	Every Business Day
Name of Guarantor	N.A.	Expense Ratio for the financial year ended 30 November 2022	A – SGD 1.95% A – USD 1.95%
Share Class	AB International Health Care Portfolio – A SGD AB International Health Care Portfolio – A USD		

### ILP SUB-FUND SUITABILITY

#### WHO IS THE ILP SUB-FUND SUITABLE FOR?

The ILP Sub-Fund is only suitable for potential investors who:

- Have higher risk-tolerance and are seeking the medium to long term rewards of equity investment.

#### Further Information

Refer to Section 5 and Section 7 of the Fund Summary for further information on the ILP Sub-Fund.

### KEY FEATURES OF THE ILP SUB-FUND

#### WHAT ARE YOU INVESTING IN?

The ILP Sub-Fund invests 100% into AB International Health Care Portfolio (the "Portfolio"). The Portfolio is an open-ended investment company with variable capital domiciled in Luxembourg, that is regulated by the Commission de Surveillance du Secteur Financier and qualifies as a UCITS under European Union directives.

The investment objective of the Portfolio is to seek capital appreciation through investments on a worldwide basis in equity securities of companies that are engaged in

Refer to Section 2, Section 5 and Section 16 of the Fund Summary for further information on features of the ILP Sub-Fund.

<sup>1</sup>The ILP Sub-Fund is not classified as Excluded Investment Product.

<p>health care and health science industries. The Board currently does not intend to declare a dividend with respect to any Share class and therefore any net income and net realised profits attributable to the Shares will be reflected in the respective NAV of the Shares.</p>	
<p><b>Investment Strategy</b></p>	
<p>The Portfolio expects to invest at least 80% of its net assets in securities of companies principally engaged in healthcare and healthcare-related industries from both developed and emerging-market countries. The Portfolio invests in companies that are expected to profit from the development of new products and services for emerging technologies and services in health care industries. The companies may include those that provide traditional products and services currently in use in health care industries and that are likely to benefit from any increases in the general demand. The Portfolio may invest in both smaller, less-seasoned companies as well as larger, well-established companies.</p> <p>The Portfolio is entitled to use derivative instruments for hedging or efficient portfolio management ("EPM") purposes.</p>	<p>Refer to Section 5 of the Fund Summary for the further information on the investment focus and approach of the ILP Sub-Fund.</p>
<p><b>Parties Involved</b></p>	
<p><b>WHO ARE YOU INVESTING WITH?</b></p> <p>The Investment Manager of the Portfolio is AllianceBernstein L.P., a Delaware limited partnership.</p> <p>Brown Brothers Harriman (Luxembourg) S.C.A. has been appointed to act as Administrator and Depositary.</p>	<p>Refer to Section 3 of the Fund Summary for further information on the roles and responsibilities of these entities and what happens if they become insolvent.</p>
<p><b>KEY RISKS</b></p>	
<p><b>WHAT ARE THE KEY RISKS OF THIS INVESTMENT?</b></p> <p>The value of investments and the income from them, and therefore the value of, and income from, Shares relating to the Portfolio can go down as well as up and you may not get back the amount you invest.</p> <p>These risk factors, among others, may cause you to lose some or all of your investment:</p>	<p>Refer to Section 7.1 of the Fund Summary for further information on risks of the ILP Sub-Fund.</p>
<p><b>Market and Credit Risks</b></p>	
<p><b>You are exposed to global Country Risks.</b></p> <p>Investments in issuers located in a particular country or geographic region may have more risk because of particular market factors affecting that country or region.</p> <p><b>You are exposed to Currency Risks.</b></p> <p>Investing in global securities exposes the Portfolio to fluctuations in currency exchange risk, which may negatively affect the value of the investment or reduce returns. as a result.</p>	<p>Refer to Section 7.2 of the Fund Summary for further information on market risk of the Underlying Sub-Fund.</p>
<p><b>Liquidity Risks</b></p>	
<p><b>The Shares are not listed and can only be realised on Business Days.</b></p> <p>There is no secondary market for the Shares. All realisation requests should be submitted in the manner set out in the Singapore Prospectus.</p> <p><b>You may not be able to redeem when a redemption limit is imposed or when redemption is suspended.</b></p> <p>A redemption limit may be imposed if requests are received to redeem more than 10% of the Shares of the Portfolio outstanding. Further, your right to redeem may be temporarily suspended under certain circumstances as set out in the Singapore Prospectus</p>	<p>Refer to Section 7.1 of the Fund Summary for information on liquidity risks of the ILP Sub-Fund and Section 9 of the Fund Summary for further information on Suspension of Dealings of the ILP Sub-Fund.</p>
<p><b>Product-Specific Risks</b></p>	
<p><b>You are exposed to Derivatives Risks.</b></p> <p>The Portfolio is entitled to use derivative instruments for hedging and EPM purposes which may involve additional risks different from, and, in certain cases, greater than, the risks presented by more traditional investments. Some of the risks associated with derivatives are market risk, management risk, credit risk, liquidity risk and leverage risk.</p>	<p>Refer to Section 7.2 of the Fund Summary for further information on specific risks of the Underlying Sub-Fund.</p>

In adverse situations, the Portfolio's use of derivative instruments may become ineffective in hedging or EPM and the Portfolio may suffer significant losses. The failure of a counterparty to a derivative contract to comply with the terms of the derivative contract could cause the Portfolio to suffer a loss.

**You are exposed to Focused Portfolio Risk.**

The Portfolio may invest in a limited number of issuers, industries or sectors or countries and may therefore be subject to greater volatility than a portfolio invested in a larger or more diverse array of securities. Such concentration could expose such investors to losses disproportionate to market movements in general if there are disproportionately greater adverse price movements in securities in which the Portfolio is invested.

**FEES AND CHARGES**

**WHAT ARE THE FEES AND CHARGES OF THIS INVESTMENT?**

Payable directly by you as a percentage of your investment amount:

<b>Premium Charge*</b>	Currently Nil
<b>Surrender Penalty*</b>	Surrender penalty may apply. You should also refer to the Product Summary for information on the surrender penalty, if applicable.
<b>Switching Fee*</b>	Currently Nil

Payable by the ILP Sub-Fund from asset value of the Portfolio:

<b>Annual Management Fee</b>	Currently 1.80% p.a.*
<b>Other fees</b>	Management Company fee: 0.05%; Depositary fee: 0.01% Transfer Agent fee: 0.06%; Administrator fee: 0.02%; Any other charges: 0.04%

\* HSBC Life reserves the right to review and amend the fees and charges by giving you at least thirty (30) days' advance notice.

Refer to Section 8 of the Fund Summary and Section 5 of the Product Summary for further information on fees, charges and Surrender Penalty (if applicable).

**VALUATIONS AND EXITING FROM THIS INVESTMENT**

**HOW OFTEN ARE VALUATIONS AVAILABLE?**

The indicative NAV per Share should be available two Business Days after the relevant Valuation Date. The NAV will also be available on [www.alliancebernstein.com](http://www.alliancebernstein.com).

**HOW CAN YOU EXIT FROM THIS INVESTMENT AND WHAT ARE THE RISKS AND COSTS IN DOING SO?**

You can exit or partially exit the ILP Sub-Fund at any time by informing HSBC Life (Singapore) Pte. Ltd. ("HSBC Life"), either directly or through your Financial Consultant from whom you purchased the ILP Sub-Fund. If your application reaches our correspondence address before 3.30pm on a business day, it will be processed on the same business day. If your application is received after 3:30pm, it will be processed on the next business day. The units withdrawn will be realised at the unit price of the ILP Sub-Fund on the valuation date immediately following the date we accept your written application. The withdrawal proceeds will usually be paid out within 6 business days from the day we process your valid application to exit or partially exit the ILP Sub-Fund.

The following is an illustration of the withdrawal amount\*\* that you will receive from the ILP Sub-Fund based on withdrawal of 1,000 units, and unit price of \$1.50 assuming the policy is surrendered in the first year with surrender penalty charge of 70% on the account value.

$$(1,000 \times \$1.50) - 70\% (1,000 \times \$1.50) = \$450$$

Gross withdrawal amount - surrender penalty charge = Net withdrawal amount

\*\* You should also refer to the Product Summary for information on any surrender penalty that may be applicable.

If you decide to terminate the Investment-Linked Policy within the free-look period of receiving your Investment-Linked Policy, HSBC Life will refund the initial premium you paid without interest, without incurring the fees and charges as stated above, less any medical and/or underwriting expenses incurred in accepting your application; and a

Refer to Section 13 of the Product Summary for more information on valuation, and Sections 7 and 8 of the Product Summary for more information on withdrawal and switching.

sum to account for market fluctuation in respect of your units as determined by HSBC Life. Please note that no top-up, fund switching, partial withdrawal or surrender is allowed during the free-look period.	
<b>CONTACT INFORMATION</b>	
<b>HOW DO YOU CONTACT US?</b> Please contact your Financial Consultant or call Customer Service Hotline at +65 6880 4888, Mondays to Fridays (excluding public holidays), 9am to 5pm.	
<b>GLOSSARY</b>	
<p><b>“Board”</b> – The Board of Directors of the Portfolio.</p> <p><b>“Business Day”</b> – A day (other than Saturday, Sunday or a gazetted public holiday) on which commercial banks are open for business in Singapore.</p> <p><b>“NAV”</b> - means the value of the total assets of a portfolio less the total liabilities of such portfolio.</p> <p><b>“Trade Day”</b> - The Business Day as of which any transaction in Shares (purchase, redemption or exchange) for a portfolio is recorded in the shareholder register of the Fund, in respect of one or more portfolios, as the context requires, as having been accepted.</p> <p><b>“Valuation Date”</b> - The relevant Business Day on which the NAV of a class of Shares is determined.</p>	